The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide
Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fasting conditions using a
single-dose, 2-treatment, 2-period, crossover design.
- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening.
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Torsemide or any comparable or similar